Brief: UroGen Pharma Announces Exclusive License Agreement With Agenus Inc To Advance Treatment Of Urinary Tract Cancers

UroGen Pharma

11/11/2019 13:18

Nov 11 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH
AGENUS
INC TO ADVANCE TREATMENT OF URINARY TRACT CANCERS
    * UROGEN PHARMA -  TO DEVELOP AND COMMERCIALIZE ZALIFRELIMAB
WITH
UGN-201 FOR HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    * UROGEN PHARMA LTD -  IN EXCHANGE FOR WORLDWIDE EXCLUSIVE
LICENSE
TO AGEN1884 AGENUS WILL RECEIVE AN UPFRONT PAYMENT OF $10
MILLION
    * UROGEN PHARMA LTD -  AGENUS MAY RECEIVE UP TO $115 MILLION
FOR
ACHIEVING CERTAIN CLINICAL DEVELOPMENT AND REGULATORY MILESTONES
RELATED TO AGEN1884
    * UROGEN PHARMA LTD -  AGENUS MAY RECEIVE UP TO $85 MILLION
UPON
ACHIEVING CERTAIN COMMERCIAL MILESTONES RELATED TO AGEN1884
    * UROGEN PHARMA LTD -  WILL BE RESPONSIBLE FOR ALL
DEVELOPMENT AND
COMMERCIALIZATION ACTIVITIES OF AGEN1884
    * UROGEN PHARMA - WORLDWIDE LICENSE DOES NOT INCLUDE
ARGENTINA,
BRAZIL, CHILE, COLOMBIA, PERU, VENEZUELA

Source text for Eikon:  ID:nBw6hzKpDa 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))